Neutrophils in order to Lymphocyte Percentage as a Biomarker within Bronchiectasis Exacerbation A new Retrospective Review: Revision history

Jump to: navigation, search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

17 January 2024

  • curprev 17:5017:50, 17 January 2024‎ Riflesalad63 talk contribs‎ 3,506 bytes +3,506‎ Created page with "Willingness-to-pay ratio for cost-utility examination (CUA) as well as cost-effectiveness examination (CEA) was US$50,000 for each QALY and also US$20,500 for every prevented major depression case, respectively. These kinds of ratios were utilized in the actual cost-effective acceptability necessities studies in order to estimate the prospect of cost-effectiveness of the projected incremental cost effectiveness rates (ICER) regarding BAM compared to CAU. A total of 115 a..."
Retrieved from "https://news.npo.digital/index.php?title=Neutrophils_in_order_to_Lymphocyte_Percentage_as_a_Biomarker_within_Bronchiectasis_Exacerbation_A_new_Retrospective_Review"